Percy Berrospi
A5107004741- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Acute Ischemic Stroke Management
- Antiplatelet Therapy and Cardiovascular Diseases
- Intracerebral and Subarachnoid Hemorrhage Research
- Global Public Health Policies and Epidemiology
- Lipoproteins and Cardiovascular Health
- Venous Thromboembolism Diagnosis and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Coronary Interventions and Diagnostics
- Health Systems, Economic Evaluations, Quality of Life
Laboratoire Lorrain de Recherche en Informatique et ses Applications
2023
Previous studies suggested potential ethnic differences in the management and outcomes of atrial fibrillation (AF). We aim to analyse oral anticoagulant (OAC) prescription, discontinuation, risk adverse Asian patients with AF, using data from a global prospective cohort study.From GLORIA-AF Registry Phase II-III (November 2011-December 2014 for II, January 2014-December 2016 III), we analysed according their self-reported ethnicity (Asian vs. non-Asian), as well subgroups (Chinese, Japanese,...
Abstract Background and purpose Prospectively collected data comparing the safety effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods In GLORIA-AF, a large, prospective, global registry program, consecutive AF were followed for 3 years. The comparative analyses (1) dabigatran vs rivaroxaban or apixaban (2) performed on propensity score (PS)-matched patient...
Abstract Aims Chronic Obstructive Pulmonary Disease (COPD) may influence management and prognosis of Atrial Fibrillation (AF), but this relationship has been scarcely explored in contemporary global cohorts. We aimed to investigate the association between AF COPD, relation treatment patterns major outcomes. Methods From prospective, GLORIA-AF Registry, we analysed factors associated with COPD diagnosis, as well risk outcomes COPD. Primary outcome was composite all-cause death adverse...
Abstract The 2MACE score was specifically developed as a risk-stratification tool in atrial fibrillation (AF) to predict cardiovascular outcomes. We evaluated the predictive ability of GLORIA-AF registry. All eligible patients from phase II/III prospective global registry were included. Major adverse cardiac events (MACEs) defined composite outcome stroke, myocardial infarction and death. Cox proportional hazards used examine relationship between study Predictive capability investigated...
Hypertension, hyperglycemia, dyslipidemia, overweight, obesity, and tobacco (smoking, chewing, vaping), together with a pro-inflammatory procoagulant state, are the main risk factors related to atherosclerotic cardiovascular disease.
The SAMe-TT2R2 score helps identify patients with atrial fibrillation (AF) likely to have poor anticoagulation control during vitamin K antagonists (VKA) and those scores >2 might be better managed a target-specific oral anticoagulant (NOAC). We hypothesized that in clinical practice, VKAs may prescribed less frequently AF than lower scores.We analyzed the Phase III dataset of Global Registry on Long-Term Oral Antithrombotic Treatment Patients Atrial Fibrillation (GLORIA-AF), large, global,...